Stemline Therapeutics: Clinical Trial Results With SL-701 Data To Be Presented

(RTTNews) - Stemline Therapeutics Inc. (STML) announced Tuesday that clinical trial results of SL-701, a Phase 2 therapeutic entering registration-directed studies in high-grade glioma or HGG, in an additional indication, low-grade glioma or LGG, will be presented by investigators from the University of Pittsburgh at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology or WFNO being held in conjunction with the 18th Annual Society for Neuro-Oncology or SNO meeting in San Francisco, California on November 21-24, 2013.

SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides corresponding to targets on tumor bulk and cancer stem cells or CSCs.

SL-701 has previously demonstrated single-agent clinical efficacy, including complete responses (CRs), in Phase 1/2 trials in both adults and children with high-grade glioma (HGG), including glioblastoma multiforme or GBM. Based on these results, Stemline is undertaking registration-directed programs in both adults and children with HGG.

At the SNO meeting, University of Pittsburgh investigators will report on the safety and immunological responses achieved with SL-701 in an additional indication, adults with newly diagnosed or recurrent low-grade glioma (LGG) (n=23). SL-701 was determined to be well-tolerated and induced specific and sustained immune responses against its brain tumor targets. Further, patients with a high magnitude of immunologic responsiveness experienced prolonged progression free survival or PFS.